23 results about "Vasodilator agents" patented technology

The invention discloses a method, a system and equipment for evaluating the treatment effect of an anti-aging drug Senlytics. According to the invention, it is found for the first time that the anti-aging drug Senlytics composed of dasatinib and quercetin plays an anti-aging role by inhibiting the level of JPX, BRD4, p-p65 / p65 and / or JPX-BRD4-p65 compounds, and on the basis of this, the anti-aging effect of the anti-aging drug Senlytics composed of dasatinib and quercetin is achieved. The invention provides a method, a system and equipment for evaluating the treatment effect of an anti-aging drug Senlytics composed of dasatinib and quercetin based on the expression level of JPX, BRD4, p-p65 / p65 and / or JPX-BRD4-p65 compounds for the field, and the method, the system and the equipment have wide application prospects in the aspect of evaluation of the treatment effect of cardiovascular disease drugs.

The application belongs to the technical field of biomaterial preparation, and particularly relates to a composite drug delivery system based on macrophage membranes and a preparation method and application thereof. The composite drug delivery system takes a lipid nanoparticle as a drug targeting delivery carrier, coats quercetin through an active phagocytosis mode, coats a macrophage membrane on the surface of the lipid nanoparticle, and constructs a quercetin lipid nanoparticle coated with a macrophage membrane (MCM@QU@LNP). The composite drug delivery system provided by the application can promote drug enrichment in RA lesions, improve local drug exposure, realize precise drug delivery in the RA part, has good biological safety, and reduces system toxicity.

The present application relates to the technical field of skin mucosa repair, and particularly relates to a pharmaceutical preparation for repairing skin mucosa injury. The preparation takes kaempferol, quercetin, 3-p-coumaroyl-1, 4, 6'-triacetyl sucrose, 3-p-coumaroyl-2', 3', 6'-triacetyl sucrose, (+)-syringaresinol and vitamin B12 extracted from Prunus tomentosa as active ingredients, so as to solve the problems of poor curative effect, long repair period and easy scarring of the existing skin mucosa injury repair preparation, and realize efficient, safe and high-quality skin mucosa injury repair effect.

The present application relates to the field of biotechnology, in particular to astaxanthin and dihydroquercetin co-loaded liposome and its application in preparation of uric acid-lowering products. According to the steps of "in vitro function screening - optimal ratio determination - co-loaded liposome construction - surface coating and stabilization treatment - uric acid-lowering application verification", the obtained system is verified through physicochemical characterization, stability test and animal experiment. The results show that the co-loaded liposome can reduce the serum uric acid level of high uric acid model mice, inhibit the activity of liver xanthine oxidase, and improve the related indexes of kidney function and histopathological damage.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-tumor composition, a medicine for preventing and / or treating tumors and application. The anti-tumor composition provided by the application comprises dihydroquercetin and beta-carotene; the dihydroquercetin and beta-carotene combined preparation can inhibit the proliferation and growth of various tumor cells of breast cancer, liver cancer, gastric cancer, prostate cancer, lung cancer and colorectal cancer, has an application prospect for preventing and / or treating various cancers, and meanwhile, taking breast cancer and colorectal cancer as examples, it is proved that the dihydroquercetin and beta-carotene can inhibit the tumor growth and metastasis of breast cancer and colorectal cancer. It can be seen that the composition provided by the application can significantly inhibit the proliferation, growth and metastasis of tumors, and can be used for preparing a medicine for preventing and / or treating primary and metastatic tumors.

The present application relates to a kind of double-layered lozenge for preventing and treating oral ulcer and its preparation method, the double-layered lozenge is prepared from immediate-release layer containing isoquercitrin and sustained-release layer containing selenium polysaccharide;Wherein, the weight ratio of the dosing amount of isoquercitrin and selenium polysaccharide is (7.5-20):(17.5-5), and the total weight of dosing amount is 25.The present application controls the dosage of isoquercitrin and selenium polysaccharide and the release sequence of sustained-release adhesion, forms an adhesion layer on the wound surface pretreated by isoquercitrin, can realize the advantages of improving the efficacy on oral ulcer, and adjusting oral flora balance, preventing the recurrence of oral ulcer.

The application discloses a preparation method of dihydroquercetin self-assembled nanoparticles and application of the nanoparticles in liver protection, and the preparation method of the nanoparticles is as follows: betaine and dihydroquercetin are respectively dissolved in methanol; the methanol solutions of the betaine and the dihydroquercetin are mixed in a 1:1 molar ratio, and the pH is adjusted to 7.0-7.5 by using a sodium hydroxide solution; the mixture is added into preheated PBS under stirring, sealed and kept at 55-65 DEG C for 20-40 minutes; after being cooled to room temperature, the mixture is subjected to ultra-pure water dialysis by using a dialysis bag, and the BTNPs, i.e. dihydroquercetin self-assembled nanoparticles, are obtained after freeze-drying. The nanoparticles have good ALI treatment effect, high safety, can simultaneously solve the defects of low solubility and poor bioavailability of dihydroquercetin, and the defects of betaine, such as easy occurrence of gastrointestinal adverse reactions and existence of dose-dependent safety risks; meanwhile, the nanoparticles can also regulate intestinal flora disorder caused by alcohol and prevent endotoxemia.

The present application relates to a new use of Dihydroquercetin for preventing and treating cardiac toxicity induced by arsenic trioxide, and belongs to the technical field of medicine. In order to solve the problem that the prior art lacks effective treatment means for cardiac toxicity induced by ATO, the present application provides a new use of Dihydroquercetin for preventing and treating cardiac toxicity induced by arsenic trioxide, that is, the application of Dihydroquercetin in the preparation of a medicine for preventing and treating cardiac toxicity induced by arsenic trioxide. The present application proves through experiments that Dihydroquercetin can alleviate cardiac toxicity induced by ATO in multiple ways, including alleviating ATO-induced apoptosis, ferroptosis, oxidative stress, mitochondrial dysfunction and DNA damage. The present application finds that Dihydroquercetin has an excellent effect of preventing and treating cardiac toxicity induced by arsenic trioxide, provides a new strategy for improving the safety of arsenic trioxide, provides an embedding point for preparing a new medicine for preventing and treating cardiac toxicity induced by arsenic trioxide, and has an important clinical application prospect.

This invention belongs to the field of nanobiomedicine technology, specifically relating to a mitochondrial-targeting copper-based nanoparticle (Qu@Cu-SS31) and its application in the preparation of drugs for treating myocardial infarction. The nanoparticles consist of quercetin (Que) and copper ions (Cu²⁺). + The nanoparticles, consisting of a self-assembly of the mitochondrial-targeting peptide SS31, exhibit a uniform, near-spherical morphology with an average particle size of 17.2 ± 1.6 nm. These nanoparticles specifically target cardiomyocyte mitochondria, responsively releasing Cu²⁺. + Furthermore, Qu@Cu-SS31 restores cardiomyocyte copper homeostasis by downregulating the copper metabolism negative regulator COMMD1, the copper uptake protein CTR1, and the copper chaperone protein CCS. Based on this, Qu@Cu-SS31 exhibits remarkable SOD-like and CAT-like enzyme activities, efficiently scavenging various reactive oxygen species / reactive nitrogen species and significantly reducing oxidative stress. Simultaneously, it inhibits NLRP3 inflammasome activation and Caspase-1-mediated pyroptosis, regulates the Bcl-2 / Bax balance to inhibit apoptosis, and promotes vascular endothelial growth factor expression and angiogenesis.

The present application provides a kind of drug composition and its application for targeting neuroinflammation, the composition is composed of active ingredient and natural nanometer delivery carrier for encapsulating active ingredient, the active ingredient includes fisetin, pyrrole quinoline quinone, resveratrol, bauhinia A, apigenin, saffron, quercetin and hair monkey element;The natural nanometer delivery carrier is the plant source extracellular vesicle of surface modification brain targeting molecule.The composition of the present application realizes the intervention to vascular cognitive impairment by multi-component scientific compatibility, combined with two-stage brain targeting delivery design, solves the pain points of low blood-brain barrier penetration rate and poor bioavailability of natural active ingredient, has the effect of strong anti-inflammatory and significantly improving cognitive function, excellent safety, can be used for preparing the medicine for preventing or adjuvant therapy neuroinflammation related vascular cognitive impairment, has very high clinical conversion value.

This invention discloses a dihydroquercetin cocrystal, its preparation method, and its applications. The dihydroquercetin cocrystal is prepared by combining dihydroquercetin extracted from species such as Siberian larch with small molecule substances, including betaine, L-proline, benzamide, nicotinamide, or isonicotinine. The dihydroquercetin cocrystal of this invention exhibits high thermal stability and higher apparent solubility and dissolution rate compared to dihydroquercetin itself. This facilitates the full utilization of dihydroquercetin's various pharmacological effects, such as antioxidant, antitumor, anti-apoptotic, anti-inflammatory, cardiomyocyte protection, hypoglycemic, improvement of vascular endothelial cell function, antiplatelet aggregation, and influence on bone metabolism. Furthermore, the preparation method is simple, allowing for large-scale industrial production and offering significant economic benefits.

The invention relates to the technical field of skin mucosa repair, in particular to a pharmaceutical preparation for repairing skin mucosa injury. According to the preparation, kaempferol, quercetin, 3-p-coumaroyl-1, 4, 6 '-triacetyl cane sugar, 3-p-coumaroyl-2', 3 ', 6'-triacetyl cane sugar, (+)-clove resinol and vitamin B12 which are extracted from Nanking cherries are used as active ingredients, the problems that an existing skin mucous membrane injury repairing preparation is poor in curative effect, long in repairing period, prone to scar remaining and the like are solved, and the efficient, safe and high-quality skin mucous membrane injury repairing effect can be achieved.

The application belongs to the field of drug delivery and particularly relates to a composite porous stent, a composite porous drug delivery system and application. The composite porous stent comprises crosslinked oxidized hyaluronic acid, methacrylated xanthan gum, gelatin and sodium alginate; the composite porous drug delivery system is constructed by loading hyaluronic acid-coated quercetin and ginsenoside Rh2 nanoparticles on the composite porous stent, and can precisely and targetedly deliver the loaded traditional Chinese medicine components to a lesion site, so as to achieve the purpose of high-efficiency, safe and targeted treatment of breast cancer.

The invention relates to a dihydroquercetin nano preparation and application thereof in treatment of pulmonary nodules, the dihydroquercetin nano preparation is in an irregular spherical shape, C, O, N and Ce elements coexist, the molar ratio of Ce < 4 + > to Ce < 3 + > is 1.57, and the dihydroquercetin nano preparation has enzyme-like activity of superoxide dismutase, catalase, peroxidase and glutathione and can realize enzyme cascade reaction; the preparation method of the dihydroquercetin nano preparation comprises the following steps: step 1, respectively dissolving Ce (NO3) 3.6 H2O and dihydroquercetin in a beaker filled with methanol; and 2, adding the two solutions into a beaker filled with a PEG 8000 methanol solution, starting an assembly process, and stirring at room temperature to obtain qualified CeDHQNCs, namely the dihydroquercetin nano preparation. The dihydroquercetin nano preparation shows excellent enzyme-like activity and high active oxygen scavenging ability, can inhibit pulmonary nodule growth and inflammation infiltration, and provides a new means for pulmonary nodule treatment.

The invention discloses radix astragali and radix ginseng palpitation relieving granules and a quality detection method thereof. The optimal forming process of the radix astragali and radix ginseng palpitation relieving granules is screened out through a large number of experiments. According to the invention, the optimal thin-layer chromatography development condition is screened out, and qualitative identification research is carried out on salvia miltiorrhiza, radix astragali preparata and ligusticum wallichii in the quality detection method of the radix astragali, radix astragali and radix astragali palpitation relieving granules. According to the present invention, the optimal fluidity composition, the gradient elution mode and other chromatographic conditions are screened through a large number of experiments, the fingerprint detection method with characteristics of high precision, good stability and high accuracy is established, and the contents of the effective components such as calycosin-7-glucoside, ferulic acid, dihydroquercetin, ammonium glycyrrhizinate, nardosinone and the like can be simultaneously determined; and a quality detection method is provided for ensuring the safety and the effectiveness.

The invention belongs to the technical field of biological medicines, and particularly relates to a preparation method and application of an anti-hepatic fibrosis nano-drug. The drug is a macrophage membrane coated dihydroquercetin loaded PLGA nanoparticle, PLGA-PEG is used as a nano-carrier to load an anti-hepatic fibrosis active component dihydroquercetin, and the outer layer is coated with a macrophage membrane to construct a bionic drug delivery system. Results of embodiments prove that the nano-drug provided by the invention can be selectively enriched in hepatic fibrosis focuses, can accurately release dihydroquercetin, cooperatively intervenes the hepatic fibrosis process through multiple ways such as oxidation resistance, inflammation resistance, hepatic stellate cell activation inhibition and immune microenvironment regulation, has small influence on normal hepatic tissues, and can be used for preparing a drug for treating hepatic fibrosis. Good clinical transformation potential is realized.

The invention relates to the technical field of biological medicines, in particular to a pharmaceutical composition with a synergistic anti-aging effect as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition specifically consists of dihydroquercetin and fisetin. According to the invention, two core anti-aging mechanisms of oxidation resistance and senescence cell removal are organically integrated for the first time, and multi-target collaborative intervention on the senescence process is realized. Compared with a single component, the composition not only can effectively repair oxidative damage, but also can selectively remove accumulated senescent cells, plays a role from the source and the result at the same time, overcomes the defects that a traditional single strategy is single in action path and limited in effect, and has a good application prospect. A more comprehensive and efficient new scheme is provided for delaying senescence and preventing and treating senescence-related diseases.

The invention discloses a composition for preventing and / or treating osteoporosis and application thereof, and relates to the technical field of biological medicine. The composition comprises gnetum alcohol and quercetin in a mass ratio of 1: (1-15). According to the composition disclosed by the invention, the gnetum alcohol blocks an NLRP3 / Caspase1 / GSDMD channel in a targeted manner, osteoblast inflammatory pyroptosis is accurately inhibited, and the inflammatory microenvironment of an osteoporosis region is improved from the source; the quercetin is capable of efficiently removing oxidative stress products, reducing cascade injury, directionally promoting osteoblast proliferation and differentiation and improving local bone regeneration capacity; the two components form a complementary synergistic effect, so that the pyroptosis-mediated pathological source is cut off, the injury progress is intervened, the bone repair microenvironment is synchronously improved, the new bone formation is promoted, and the limitation of single target treatment is broken through, and the curative effect is remarkably superior to that of single medication when the medicine is used for preventing and / or treating osteoporosis.

The application discloses a kind of pharmaceutical composition, preparation and preparation method of treating fibromyalgia syndrome, it is related to chronic pain disease treatment technical field.The pharmaceutical composition includes white flesh lucid ganoderma polysaccharide, quercetin, hesperetin and naringenin.The application further discloses a kind of pharmaceutical preparation for treating fibromyalgia syndrome and preparation method thereof.The pharmaceutical composition can effectively solve the problems of poor effect, high recurrence rate and obvious side effects of existing fibromyalgia syndrome treatment drugs;The application uses natural product to be matched, side effect is small, and can significantly improve the improvement effect on the core symptom of fibromyalgia syndrome.

The invention discloses a knee joint injury repairing agent based on stem cells and a preparation method and application thereof, and belongs to the technical field of knee joint injury repairing, the knee joint injury repairing agent comprises adipose-derived mesenchymal stem cells, astragalus polypeptide, autologous knee joint bone meal, a traditional Chinese medicine extract A, a traditional Chinese medicine extract B, hyaluronic acid and quercetin, and a proper amount of PBS buffer solution with the pH value of 7.5 is dissolved. Autologous knee joint bone meal and astragalus polypeptide are added in the adipose-derived mesenchymal stem cell culture stage, so that osteogenesis directional differentiation of stem cells is started in advance. The bone meal provides an autologous bone matrix microenvironment, the astragalus polypeptide activates an osteogenesis-related signal channel, conversion of stem cells into bone cells is remarkably accelerated through double-effect synergism, the problem that in the prior art, differentiation is delayed after the stem cells are implanted into a body is solved, and the repair efficiency is remarkably improved.

The invention discloses application of a quercetin-loaded engineered menstrual blood stem cell exosome in preparation of a medicine for treating intrauterine adhesion, and belongs to the technical field of biological medicines. The Que (at) Exo is prepared by loading quercetin in exosome from menstrual blood stem cells, and keeps the natural form, particle size and marker protein expression of the exosome. Experiments show that the Que (at) Exo can significantly improve the delivery efficiency and the residence time of quercetin at the diseased region of the uterus, and compared with free quercetin, a pure exosome and a physical mixture of the free quercetin and the pure exosome, the Que (at) Exo can more effectively promote regeneration of damaged endometrium, inhibit collagenous fiber deposition and myofibroblast activation, increase the number of endometrial blood vessels and glands, improve the curative effect of the quercetin on the diseased region of the uterus and improve the curative effect of the quercetin on the diseased region of the uterus. Therefore, intrauterine adhesion is improved, and the fertility function is improved. The invention provides an efficient and safe new biological treatment strategy for intrauterine adhesion.

The invention discloses a pharmaceutical composition for maintaining health of heart and cerebral vessels and a preparation method and application thereof.Astragalus polysaccharide, dihydroquercetin and ergothioneine are added into a compound of EGCG and chitosan oligosaccharide, so that actual benefits in formula science / stability are obtained, for example, the stability and bioavailability of EGCG are protected and improved; the traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition also has pharmacological complementarity, such as antioxidation-anti-inflammation-immunity / metabolism multiple target point complementation, system component stability is achieved, meanwhile, blood fat is effectively reduced, and heart and cerebral vessel health is maintained.

The invention provides application of a cadechin-mediated signal channel in treatment of uremic pruritus, relates to the technical field of biomedicine, provides application of the cadechin-mediated signal channel as a drug target in preparation of drugs for treatment of uremic pruritus, and firstly provides establishment of a uremic pruritus model. The establishment of the optimal model verifies that the subsequent inhibition pathway relieves uremic itching. Secondly, a cell model is also established in the application, and the existence of a TRPV1-catchin signal channel is proved in a TRPV1 overexpressed primary cell DRG and a cell line HEK293T by applying calcium imaging, a probe and other technologies to verify the TRPV1 overexpressed primary cell DRG and the cell line HEK293T; wT and a TRPV1-KO mouse are adopted to establish an itching model, and existence of a TRPV1-catchin signal channel in an animal is verified. Finally, according to the application, different doses of dihydroquercetin solutions are injected through caudal veins to detect that uremic pruritus is relieved by inhibiting a TRPV1-catchin signal channel.